new drug to treat AIDS succeeds in his first clinical test
A drug for the treatment of HIV / AIDS successfully passed the first clinical trials, where the drug is produced using a combination of antibodies.
The results of the test, published in the journal Nature, showed that the drug succeeded in curbing infection in the volunteers’ bodies for four months after giving up the use of antiretroviral drugs.
“The treatment of AIDS using antibodies gives patients hope for recovery,” said Anthony Fussie, president of the Institute of Allergy and Infectious Diseases in the United States (NIAID). “We have made an important step toward this hope. We have shown that the combination of specific antibodies can suppress Infection for a long time. ”
Three years ago, scientists at Rockefeller University in New York, headed by Marina Casci, discovered an unusual antibody, “3BNC117,” that can inhibit the multiplication of various types of HIV. The secret of this antibody is that it attacks the main part of the virus and attaches to the “tail” of the immune cells, and helps the virus to penetrate into it. The scientists tested 3BNC117, obtained from the body of an infected person two years ago, and it turned out that it can be used to curb infection for a long time.
These results prompted Kaski and her team to use “3BNC117” with another broad-spectrum antibody “10-1074”, which is used to get immunity against HIV.
The team tested this idea on a group of monkeys and the results were positive, so it was decided to test this combination of antibodies on human volunteers. Indeed, he tested eight volunteers who contracted the disease five years ago and are constantly taking antiretroviral drugs, agreeing to temporarily stop taking these drugs and just to mix the antibodies.
He also tested the combination at the same time on a group of 7 people who were infected before the disease and did not start taking treatment. Twelve volunteers out of a total of 15 resisted HIV successfully within 20 weeks, and the other three were reintroduced to traditional treatment after the virus was found to be resistant to the antibody mix, says Kaski.
Based on these results, Marina Kaski and her team intend to test the mix for 40 weeks on a larger group of volunteers.